Dose Escalation of Biologics in Biologic-Naïve Patients With Ulcerative Colitis: Outcomes From the ODESSA-UC Study

BACKGROUND: Dose escalation of biologics may regain treatment response in patients with ulcerative colitis (UC). However, dose escalation rates and associated outcomes and costs are not well characterized in biologic-naïve patients receiving antitumor necrosis factor-alpha (anti–TNF-α) treatments, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosh, Sabyasachi, Kathe, Niranjan, Umashankar, Kandavadivu, Mirchandani, Kirti, Hait, Arunima, Paul, Riyanka, Candela, Ninfa, Fan, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653026/
https://www.ncbi.nlm.nih.gov/pubmed/38028955
http://dx.doi.org/10.1093/crocol/otad061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653026/
https://www.ncbi.nlm.nih.gov/pubmed/38028955
http://dx.doi.org/10.1093/crocol/otad061

Ejemplares similares